Janux Therapeutics (NASDAQ:JANX) Earns “Outperform” Rating from William Blair

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a research report issued to clients and investors on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

JANX has been the subject of several other research reports. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. Scotiabank lowered their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $48.76 on Thursday. The business’s fifty day moving average price is $49.76 and its 200 day moving average price is $46.45. The firm has a market capitalization of $2.56 billion, a PE ratio of -41.68 and a beta of 3.52. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, equities analysts anticipate that Janux Therapeutics will post -1.34 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This represents a 42.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now directly owns 7,000 shares in the company, valued at approximately $296,310. This represents a 23.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 420,610 shares of company stock valued at $19,288,666 in the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth $29,000. Amalgamated Bank increased its holdings in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth $42,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth $151,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.